TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15024929
Drug: Observed artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Observed artesunate 4 mg/kg on day 0 plus self-administered mefloquine 15 mg/kg on day 1 and 10 mg/kg on day 2 with artesunate 4 mg/kg/day on day 1 and 2
Study: 15024929
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose treatments
Study: 8005188
Drug: Intravenous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terbutaline sulphate
Study: 7586920
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline
Study: 8005188
Drug: Intravenous enprofylline
Normalized name: etofylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enprofylline
Study: 31345135
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment (IAT) with NCCT ASPECTS 7 to 10
Study: 31345135
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment (IAT) with NCCT ASPECTS 0 to 6
Study: 31345135
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment (IAT) with NCCT ASPECTS
Study: 31345135
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment (IAT) with diffusion weighted imaging ASPECTS
Study: 27808530
Drug: Direct cause
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct cause statements (e.g., 'makes', 'increases')
Study: 27808530
Drug: Can cause
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Can cause statements (e.g., 'can make', 'can increase')
Study: 27808530
Drug: Moderate cause
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate cause statements (e.g., 'might cause', 'linked', 'associated with')
Study: 24060195
Drug: Therapist-aided exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-aided exposure therapy
Study: 12195755
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of pregnancy during breast cancer treatment
Study: 12195755
Drug: Potentially curative
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially curative therapies administered during pregnancy
Study: 12195755
Drug: Pregnancy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnancy after treatment for breast cancer
Study: 11477817
Drug: Embolism chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolism chemotherapy (ECT)
Study: 11477817
Drug: Embolism chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolism chemotherapy (ECT) + immunotherapy
Study: 11477817
Drug: Embolism chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolism chemotherapy (ECT) + Chinese herbal medicine
Study: 8017869
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon-beta 1b
Study: 31188734
Drug: GnRH Agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH Agonist
Study: 31188734
Drug: GnRH Antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH Antagonist
Study: 21668425
Drug: Narrowband ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband ultraviolet B (NB‐UVB) phototherapy, 210 mJ cm(‐2) starting dose, increased by 10% each time, administered three times per week for 6 weeks.
Study: 11390337
Drug: Immunoadsorption (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption (IA) therapy and subsequent immunoglobulin (IgG) substitution
Study: 8304047
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin (200 IU/day, two times)
Study: 3461385
Drug: Single 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 600 mg dose of trimethoprim
Study: 22417905
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (5%)
Study: 18226326
Drug: Ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/20 mg combination tablet (EZE/SIMVA)
Study: 18226326
Drug: Doubling statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling statin dose
Study: 14517196
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg once daily for mild hepatic insufficiency patients
Study: 14517196
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg every-other-day for moderate hepatic insufficiency patients
Study: 14517196
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous doses of etoricoxib for both mild and moderate hepatic insufficiency patients
Study: 8477136
Drug: PCA +
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA + CI (Patient-Controlled Analgesia plus Continuous Infusion)
Study: 27468541
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with basic treatment
Study: 27544742
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT) achieved group (548 patients, 18.2%)
Study: 27544742
Drug: Non-Optimal Medical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Optimal Medical Therapy (non-OMT) group (2,456 patients)
Study: 27544742
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT) achieved group
Study: 27544742
Drug: Non-Optimal Medical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Optimal Medical Therapy (non-OMT) group
Study: 24362587
Drug: HBO and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO and intranasal mometasone furoate (10 μl/day)
Study: 24362587
Drug: HBO and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO and diclofenac sodium (10 mg/kg/day ip)
Study: 7697841
Drug: Hirulog 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 0.5 mg/kg per hour for 12 hours followed by 0.1 mg/kg per hour
Study: 7697841
Drug: Hirulog 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 1.0 mg/kg per hour for 12 hours followed by placebo
Study: 7697841
Drug: Heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000 U bolus followed by 1000 U/h titrated to an aPTT 2 to 2.5 times control after 12 hours
Study: 9140320
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) given immediately after verapamil 80 mg (conventional formulation)
Study: 9140320
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) given 2 hours after verapamil 80 mg (conventional formulation)
Study: 9140320
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) given immediately after verapamil 240 mg (slow-release formulation)
Study: 9140320
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) given 2 hours after verapamil 240 mg (slow-release formulation)
Study: 9140320
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) given 4 hours after verapamil 240 mg (slow-release formulation)
Study: 3904433
Drug: isoxicam (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoxicam (200 to 400 mg per day, then reduced to 200 mg per day)
Study: 23861093
Drug: Parent alliance
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent alliance with therapist in Family-Based Treatment (FBT)
Study: 22480146
Drug: Adjuvant insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant insulin therapy
Study: 17313718
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 3 x 4 g/d for 6 months
Study: 11533794
Drug: Ketotifen (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (0.13 mg/kg body wt) with Chloroquine
Study: 11533794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Chloroquine, Ketotifen, and Fansidar
Study: 9107182
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus aspirin (325 mg/d)
Study: 1526054
Drug: Blocks of
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocks of the infraorbital, infratrochlear and external nasal nerves by intranasal infiltration
Study: 2861067
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nebulized fenoterol (group A)
Study: 2861067
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg fenoterol and 0.5 mg ipratropium (group B)
Study: 30913162
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CM) 0.3 g·kg⋅d for 1 week (loading phase) and 5 g·d for 7 weeks (maintenance phase)
Study: 19048243
Drug: Exogenous alkaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions or 24-72 h continuous IV infusion (132.5-200 U kg(‐1) 24 h(‐1))
Study: 19048243
Drug: Exogenous alkaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions
Study: 19048243
Drug: Exogenous alkaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous alkaline phosphatase (AP) administered via 24-72 h continuous IV infusion
Study: 16870769
Drug: FPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV plus LPV/RTV at 700 mg plus 400 mg/100 mg q12h simultaneously
Study: 16870769
Drug: FPV/RTV at
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 4 h
Study: 16870769
Drug: FPV/RTV at
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 12 h
Study: 8462533
Drug: Lignocaine 0.39
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 0.39 mg kg‐1
Study: 8462533
Drug: Lignocaine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 0.5 mg kg‐1
Study: 8462533
Drug: Lignocaine 0.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 0.63 mg kg‐1
Study: 8462533
Drug: Lignocaine 0.79
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 0.79 mg kg‐1
Study: 8462533
Drug: Lignocaine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1.0 mg kg‐1
Study: 2579877
Drug: Topical flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical flurbiprofen (0.1%)
Study: 30128853
Drug: L-menthol mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol mouth rinse (0.01%)
Study: 30128853
Drug: Ice ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice ingestion (1.25 g kg-1)
Study: 26410392
Drug: Filtered sugarcane
Normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered sugarcane molasses concentrate (FMC) administered as an oral supplement before a meal, with varying doses (exact doses not specified)
Study: 26410392
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (test meal 1)
Study: 22665534
Drug: Six-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-drug combination (IVA plus carboplatin, epirubicin, and etoposide)
Study: 9578178
Drug: Dipyridamole combined
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole combined with warfarin
Study: 2682348
Drug: Dietary erucic
Normalized name: behenyl erucate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary erucic acid therapy
Study: 123815
Drug: Analgesic tablets
Normalized name: Aspirin/Caffeine 400 MG-32 MG Oral Tablet [ANALGESIC TABLETS]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic tablets
Study: 25986648
Drug: Gantong Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantong Granules (high-dose, medium-dose, low-dose)
Study: 22066244
Drug: vitaprost plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitaprost plus (rectal suppositories), one suppository before going to bed 2 days before surgery and for 8 days after TUR, total course lasted for 10 days.
Study: 22066244
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitaprost plus treatment).
Study: 22066244
Drug: vitaprost plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitaprost plus (rectal suppositories).
Study: 16484571
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and omeprazole for Helicobacter pylori infection
Study: 16484571
Drug: Garlic supplement
Normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplement (aged garlic extract and steam-distilled garlic oil)
Study: 16484571
Drug: Vitamin supplement
Normalized name: Vitamin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplement (vitamins E and C and selenium)
Study: 15340534
Drug: Ganciclovir (GCV)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (GCV) + intravenous immunoglobulin (IVIG)
Study: 11142413
Drug: Piroxicam 7.5
Normalized name: piroxicam 7.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 7.5 mg/day
Study: 9771366
Drug: Control local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control local anaesthetic solution
Study: 7836713
Drug: Octreotide (100‐micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100‐micrograms bolus with a 100‐micrograms/h infusion)
Study: 3046465
Drug: Nalbuphine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.2 mg kg‐1)
Study: 3046465
Drug: Pentazocine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (0.5 mg kg‐1)
Study: 31062119
Drug: Maternal nut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal nut consumption during first pregnancy trimester (> 32 g/week)
Study: 29018896
Drug: HYP extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYP extract (900 mg)
Study: 25272653
Drug: Soybean (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean (100 mg)
Study: 25272653
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg) plus Soybean (100 mg)
Study: 18701556
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week (eow) for 24 weeks, then switched to open-label adalimumab 40 mg eow.
Study: 17642246
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of biologics
Study: 15229669
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in a warm climate (Lanzarote)
Study: 15229669
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in Norway (Control)
Study: 12395803
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2.0 mg daily
Study: 12395803
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.2 mg daily
Study: 10457878
Drug: Diltiazem (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.2 mg kg‐1)
Study: 10457878
Drug: Metoprolol (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.02 mg kg‐1)
Study: 10457878
Drug: Verapamil (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.05 mg kg‐1)
Study: 7788574
Drug: Double-blind oral
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind oral challenge with food additives (monosodium glutamate, tartrazine, sulfites, erythrosine, paraoxybenzoate, sodium benzoate, lactose, aspirin, and annate) under placebo control
Study: 7788574
Drug: Skin-prick tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-prick tests and patch tests
Study: 1972605
Drug: Ranitidine (histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (histamine H2-receptor antagonist)
Study: 417376
Drug: Ethchlorvynol 500
Normalized name: ethchlorvynol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethchlorvynol 500 mg for 14 days
Study: 417376
Drug: Ethchlorvynol 500
Normalized name: ethchlorvynol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethchlorvynol 500 mg
Study: 24517082
Drug: Hydrocodone extended
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone extended release (20-100 mg every 12 hours)
Study: 11374333
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olanzapine
Study: 11844887
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg olanzapine
Study: 11844887
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg olanzapine
Study: 11844887
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg or 10 mg olanzapine
Study: 2260873
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (adreno‐oophorectomy, H)
Study: 2260873
Drug: Chemotherapy (FAC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (FAC, C)
Study: 2260873
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (FAC + tamoxifen, H'C)
Study: 2260873
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (FAC + adreno‐oophorectomy, HC)
Study: 30242948
Drug: liraglutide 0.6
Normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 0.6 mg daily, titrated to 1.2 mg after the first week
Study: 28591244
Drug: Probiotic fermented
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic fermented milk beverage (150 mL for 60 days)
Study: 28591244
Drug: Non-probiotic milk
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-probiotic milk (150 mL for 60 days)
Study: 24084800
Drug: Usual obstetric
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual obstetric care and osteopathic manual treatment (UOBC+OMT)
Study: 24084800
Drug: Usual obstetric
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual obstetric care and sham ultrasound therapy (UOBC+SUT)
Study: 18851771
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy for psychosis (CBTp)
Study: 16778608
Drug: 2 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 4 mL/sec
Study: 16778608
Drug: 2 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 3 mL/sec
Study: 14534763
Drug: Immunoglobulin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given before day 5 of illness
Study: 14534763
Drug: Immunoglobulin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given on or after day 5 of illness
Study: 12374709
Drug: TSA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSA with 20 mL of 1.5% lidocaine (TSA-Lido)
Study: 12374709
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion with 300 mg of lidocaine (i.v.-Lido)
Study: 10215748
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1000 mg every 8h
Study: 10215748
Drug: Oral trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimethoprim 200 mg once daily
Study: 10215748
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs concomitantly
Study: 8642904
Drug: Atropine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.03 mg/kg)
Study: 8642904
Drug: Atenolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (10 mg)
Study: 2338194
Drug: Lovastatin, 40
Normalized name: Lovastatin, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin, 40 mg, twice a day
Study: 2338194
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 10 mg/kg per day
Study: 2338194
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lovastatin and ursodeoxycholic acid
Study: 29959787
Drug: Elobixibat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elobixibat 2.5 mg